Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNanosonics Ltd

Nanosonics Ltd

Healthcare Medical Instruments & Supplies
PortfolioPortfolio WatchlistWatchlist
Company price
2.89 AUD -0.06 ( 2.03%)
Last update at 2026-11-06T06:17:00Z
VOLUME
713787
Market Cap
882.54M
P/E
49.17

Momentum Score

…

Nanosonics Limited engages in the manufacture and commercialization of infection control and decontamination products and related technologies in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. It offers trophon, an automated ultrasound probe high-level disinfection device built on hydrogen peroxide chemistry with integrated digital traceability solutions, as well as related consumables and accessories. The company also provides infection control and decontamination products and related technologies. In addition, it is involved in the research, development, and commercialization of the CORIS system, an automated technology designed to transform flexible endoscope reprocessing. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.87
Low
2.95
High
52 Week Price Range
2.64
Low
4.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Nanosonics Ltd makes infection-prevention products for healthcare, best known for the trophon high‑level disinfection system and related single‑use consumables for ultrasound probes. Long-term growth may be driven by an expanding installed base with recurring consumable sales, stronger hospital infection‑control standards, and further international market penetration.
Principal risks include dependence on the trophon platform and consumables concentration, competitive and regulatory challenges that could slow adoption, and exposure to hospital purchasing cycles and international execution.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
2.95
Dividend Yield
-
Revenue TTM
203.89M
Revenue Per Share
0.67
Gross Profit TTM
156.81M
Debt / Equity
0.11
ROE
8.35%
Net Debt
-132.09M
ROCE
5.61%
Diluted EPS TTM
0.06

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax 20.11M 22.29M 12.99M 21.60M 1.58M
Net income 17.84M 20.68M 12.97M 19.88M 3.74M
Selling general administrative 109.60M 32.09M 26.86M 23.70M 20.28M
Selling and marketing expenses - 71.87M 65.93M 60.95M 47.88M
Gross profit 148.62M 155.66M 133.99M 132.17M 91.31M
Reconciled depreciation 8.72M 8.07M 7.63M 7.14M 5.73M
Ebit 14.99M 23.75M 14.09M 22.37M 2.13M
Ebitda 23.70M 31.82M 21.72M 29.50M 7.86M
Depreciation and amortization 8.72M 8.07M 7.63M 7.14M 5.73M
Operating income 14.99M 8.93M 9.12M 17.79M 1.84M
Other operating expenses 188.48M 190.00M 160.90M 146.36M 118.54M
Interest expense 1.68M 1.46M 1.10M 0.77M 0.56M
Tax provision 2.28M 1.61M 0.01M 1.71M -2.16M
Interest income 5.79M 5.94M 4.97M 2.39M 0.35M
Net interest income 4.11M 4.48M 3.87M 1.96M -0.20M
Income tax expense 2.28M 1.61M 0.01M 1.71M -2.16M
Total revenue 203.47M 198.93M 171.56M 167.51M 119.73M
Total operating expenses 133.63M 146.73M 133.23M 121.30M 96.25M
Cost of revenue 54.85M 43.27M 37.58M 35.35M 28.41M
Total other income expense net 5.12M 13.36M 3.87M 1.64M 0.99M
Net income from continuing ops 17.84M 20.68M 12.97M 19.88M 3.74M
Net income applicable to common shares - 20.68M 12.97M 19.88M 3.74M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 310.52M 272.48M 241.88M 219.92M 187.67M
Intangible assets - 0.00M 0.01M 0.10M 0.22M
Other current assets 10.48M 0.81M 7.38M 0.39M 0.24M
Total liab 93.01M 62.57M 59.67M 56.06M 48.98M
Total stockholder equity 217.51M 209.91M 182.20M 163.86M 138.69M
Deferred long term liab - - - - 0.21M
Other current liab 21.26M - 14.34M 18.59M 16.96M
Common stock 112.96M - 114.55M 114.21M 113.86M
Capital stock 112.96M 114.86M 114.55M 114.21M 113.86M
Retained earnings 76.22M 58.39M 37.71M 24.74M 4.86M
Other liab - - - - 10.66M
Other assets - - 0.00M 15.36M 13.62M
Cash 155.22M 161.29M 129.55M 112.16M 94.51M
Cash and equivalents - - - 1.84M 2.09M
Total current liabilities 43.28M 39.79M 32.23M 33.03M 29.16M
Current deferred revenue 15.13M - 11.27M 7.80M 6.90M
Net debt -132.09M - -120.25M -101.44M -82.80M
Short term debt 2.96M - 3.14M 2.88M 2.55M
Short long term debt total 23.13M - 9.30M 10.72M 11.71M
Other stockholder equity - - 0.00M -138.95M -118.71M
Property plant equipment - - - 22.50M 22.58M
Total current assets 239.98M 225.32M 197.79M 181.62M 151.25M
Net tangible assets - - - - 138.47M
Short term investments - - - 88.48M 72.75M
Net receivables 46.68M 32.31M 40.62M 38.75M 28.39M
Inventory 27.59M 18.63M 20.24M 25.49M 22.61M
Accounts payable 3.92M 1.53M 3.47M 3.76M 2.74M
Accumulated other comprehensive income 28.32M - 29.94M 24.91M 19.98M
Non currrent assets other 1.27M 2.06M 1.18M 0.41M 0.28M
Non current assets total 70.54M 47.16M 44.08M 38.30M 36.42M
Capital lease obligations 23.13M 7.69M 9.30M 10.72M 11.71M
Long term debt total - - - 7.84M 9.16M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -8.71M -2.36M -3.54M -6.90M
Change to liabilities - - - 0.00M 5.42M
Total cashflows from investing activities -5.14M -8.71M -2.36M -3.54M -6.90M
Net borrowings -3.11M - - - -2.04M
Total cash from financing activities -23.53M -3.30M -3.01M -2.71M -1.97M
Change to operating activities - - - - 1.14M
Net income 17.84M 20.68M 12.97M 19.88M 3.74M
Change in cash -6.42M 32.09M 17.39M 17.65M -1.51M
Begin period cash flow 161.64M 129.55M 112.16M 94.51M 96.03M
End period cash flow 155.22M 161.64M 129.55M 112.16M 94.51M
Total cash from operating activities 22.55M 43.98M 22.78M 23.31M 6.70M
Issuance of capital stock 0.20M 0.31M 0.33M 0.36M 0.32M
Depreciation 8.72M - 7.63M 7.01M 5.48M
Other cashflows from investing activities - 0.02M 0.15M 0.03M 0.06M
Change to inventory -8.96M 1.45M 3.13M -3.01M -10.74M
Change to account receivables -8.69M 2.43M -0.96M -9.00M 4.22M
Sale purchase of stock -20.00M 0.31M 0.33M 0.36M 0.32M
Other cashflows from financing activities -3.73M -3.61M -3.34M -3.07M -2.29M
Change to netincome - - - - -2.82M
Capital expenditures 5.14M 8.72M 2.52M 3.57M 6.97M
Change in working capital -12.57M 11.32M 3.24M -12.01M -6.52M
Stock based compensation - - 4.26M 5.46M 2.82M
Other non cash items 8.57M 32.66M -1.06M -3.58M -2.53M
Free cash flow 17.41M 35.26M 20.27M 19.74M -0.27M

Peer Comparison*

Sector: Healthcare Industry: Medical Instruments & Supplies

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NAN
Nanosonics Ltd		 -0.06
2.03%		 2.89 49.17 78.12 4.33 4.02 3.64 24.30
RMD
Resmed Inc		 0.14
0.40%		 34.75 21.77 19.57 8.49 5.53 5.50 14.10
FPH
Fisher & Paykel Healthcare Corporation Ltd		 0.31
0.80%		 39.20 55.56 48.54 9.91 12.92 11.78 33.96
ANN
Ansell Ltd		 0.14
0.31%		 45.66 21.27 22.73 2.99 2.16 2.24 12.03
AHC
Austco Healthcare Ltd		 -0.01
3.64%		 0.27 13.75 16.31 1.09 1.63 0.94 5.71

Profile*

Nanosonics Ltd

Nanosonics Limited engages in the manufacture and commercialization of infection control and decontamination products and related technologies in Australia, North America, Europe, the United Kingdom, the Middle East, and Asia Pacific. It offers trophon, an automated ultrasound probe high-level disinfection device built on hydrogen peroxide chemistry with integrated digital traceability solutions, as well as related consumables and accessories. The company also provides infection control and decontamination products and related technologies. In addition, it is involved in the research, development, and commercialization of the CORIS system, an automated technology designed to transform flexible endoscope reprocessing. The company was incorporated in 2000 and is headquartered in Macquarie Park, Australia.

Building A, Macquarie Park, NSW, Australia, 2113

61 2 8063 1600

https://www.nanosonics.com.au

508

Name Title Year Born
Mr. Michael C. Kavanagh BSc, M.B.A. CEO, Pres, MD & Exec. Director NA
Mr. McGregor Grant BEc, C.A., CA, FCIS, GAICD CFO & Company Sec. NA
Mr. Rod Lopez M.B.A. Chief Operating Officer NA
Dr. Steven Farrugia BE, Ph.D. Chief Technology Officer NA
Mr. David N. Morris Chief Strategy Officer & Regional Pres Asia Pacific NA
Matthew Carbines B.Com., L.L.B. Gen. Counsel NA
Mr. Matthew Lipscombe B.E., B.Sc., M.B.A. Chief Marketing Officer NA
Ms. Jodi Sampson Chief People & Culture Officer NA
Mr. Vincent Wang Head of Global Customer Support & Technical Services NA
Mr. Keith Koby Sr. VP of Sales - North America NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…